AIN
Intelligent Workspace

Intelligent Workspace

location_on California ,  United States

The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Investors should carry out their own due diligence and take professional advice where necessary.

Short Summary

Adeeno is an AI-powered workspace designed to enhance CMC teams' efficiency in drug development and regulatory workflows. It streamlines complex tasks such as study design planning, technical document compilation, and contextual data interpretation.

Highlights

  • life science industry is outdated and archaic primed to be disrupted by ai
  • major investment in drug discovery, not much on drug development machinery
  • expanding the top of the funnel doesn't mean faster drug development (neck)
  • there are little cohesive ai solutions to help the scientists do their job
  • this platform will revolutionize how we develop drugs

Overview

Target £375,000
Minimum £20,000
Investment Raised £0
Previous Rounds £0
Stage MVP/Finished Product
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects

This promotion is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds it is made exclusively to ‘investment professionals’ within the meaning of Article 19 of the Financial Services and Markets Act (Financial Promotion) Order 2005 (FinProm); persons believed on reasonable grounds to be ‘certified high net worth individuals’ within the meaning of Article 48 FinProm; persons who are ‘certified sophisticated investors’ within the meaning of Article 50 FinProm; and persons who are ‘self-certified sophisticated investors’ within the meaning of Article 50A FinProm.

If you are in any doubt about the investment to which this email relates, you are strongly recommended to consult an appropriately authorised financial adviser qualified to give advice in relation to investment. This investment opportunity will not necessarily be suitable for all recipients of this email. Applications to subscribe for shares will only be accepted at the company's discretion from persons eligible to invest.